Home » Newsletters » BioWorld Science

BioWorld Science

April 2, 2002

View Archived Issues

MMP inhibitors with activity in animal model of periodontitis

Triacetylshikimic acid: a potent and safe oral antiplatelet agent

Administration of antarelix associated with acute delay in folliculogenesis, followed by recovery

Topical GDNF improves behavioral and histological deficits in neonatal rat model of Erb palsy

Intrauterine growth restriction demonstrated for TNP-470 in later stages of pregnancy

Inhibitor of TGF-beta activity useful for fibrotic disorders

Pharmacia studies new kinase inhibitors and potential uses

Bradykinin antagonists from Pfizer useful for asthma, rhinitis, pain and inflammation

Several series of antihistamine compounds designed by Ortho-McNeil

Novel tryptase inhibitors revealed in recent patent by BMS

Antiangiogenic pyridopyrimidinones in development at Pfizer

Suberanilohydroxamic acid decreases production of proinflammatory cytokines in vivo

Novavax presents new results on Estrasorb at Society of Gynecologic Investigation meeting

Potential of hedgehog antagonists in the treatment of basal cell carcinoma

New uses for botulinum toxin type A under investigation

Approvable letter received for Metadate sprinkle administration

Elan appoints UCB as U.S. copromotion partner for Frova

Positive results achieved for Atrisone in topical treatment of acne

FDA sets date to review Biogen's Amevive

CTV-05 fails to meet primary endpoint in phase II trial

First thyroid hormone receptor modulator from BMS/Karo Bio collaboration discontinued

Positive phase IIa results achieved by HCT-1026 in overactive bladder

Sucampo licenses development and marketing rights to eye drop formulation of tacrolimus

Dyax obtains rights to inflammation target from Center for Blood Research

BB-10153 cleared to enter phase II trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.